TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Clinical and Urgent Colonoscopy Outcomes Using the Pure-Vu® Cleansing System

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalized patients in the ICU or the RNF with acute LGIB (defined as maroon-colored stool or bright red blood per rectum with suspicion of acute blood loss anemia, and hemodynamically stable and/or stabilized at the time of procedure . Hospitalized patients include:~  * Patients who develop LGIB while admitted for different reasons~ * Patients transferred from an outside hospital for further management of acute LGIB~ * Patients admitted through the emergency room for management of acute LGIB~* At least 22 years old~* Undergoing urgent colonoscopy under monitored anesthesia care or conscious sedation~Exclusion Criteria:~* Suspicion for bowel obstruction/ stricture~* Toxic megacolon or severe colitis (determined by degree of colitis on imaging and clinical condition including pain, fevers, abdominal exam, elevated inflammatory markers)~* Active Diverticulitis

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pure-Vu Treatment (Type: EXPERIMENTAL): Participants in this arm will undergo colonoscopy using the Pure-Vu cleansing device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Ocrelizumab in Autoimmune Encephalitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 or greater~2. Able to obtain informed consent from patient or appropriate designee~3. Possible autoimmune encephalitis as defined by Table 1:~   1. Reasonable exclusion of alternative causes~  2. Subacute onset (\< 3 months) of memory deficits, altered consciousness, and/or psychiatric symptoms~  3. One or more of the following:~      * CSF (cerebrospinal fluid) pleocytosis (\>5 cells/µl corrected, if necessary, for traumatic lumbar puncture)~     * EEG (electroencephalogram) with epileptiform or focal slow wave abnormalities involving temporal lobes~     * Brain abnormalities on T2/FLAIR MRI restricted to the mesial temporal (limbic) lobes~     * Associated dyskinesias (faciobrachial dystonic movements or orofacial dyskinesias)~4. Completed initial treatment with iv steroids (at least 3000mg solumedrol) and plasma exchange (at least 3 exchanges) within the past 8 weeks~5. Presence of one (or more) of the following autoantibodies in serum or CSF~   * NMDA receptor~  * LGI1~  * CASPR2~  * DPPX~Exclusion Criteria:~1. Prior immunosuppression treatment in past year (other than steroids, intravenous immunoglobulin and plasma exchange)~2. Active malignancy requiring chemotherapy~3. Pregnancy~4. Evidence of active hepatitis or tuberculosis infection~5. Medical condition that (in investigators opinion) precludes the use of ocrelizumab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: ACTIVE_COMPARATOR): Ocrelizumab will be administered 3 times over a 1 year study period. Subjects will receive a dose of 300 mg at week 0 (baseline) and again at week 2. The final dose of 600 mg will be administered at week 24.
- Treatment Placebo Arm (Type: PLACEBO_COMPARATOR): Saline will be used as the matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dietary Cholesterol and Defects in Cholesterol Synthesis in Mevalonate Kinase Deficiency

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Must have documented mevalonate kinase deficiency, mevalonic aciduria, or HIDS~* Must be willing to participate in most research procedures~Exclusion Criteria:~* Unable or unwilling to participate in most research procedures

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Functional Exercise on Fitness and QoL in Cancer Survivors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female, aged 18-90~* Been treated for colorectal cancer~* Cancer stages I-IV~* Cancer survivors will be eligible to participate if at least three months will have passed since their last treatment~* Those who are within 5 years of their last cancer treatment~* Participant is willing and able to give informed consent for participation in the study~Exclusion Criteria:~* Participants with previous FRT participation~* Cancer survivors with cardiovascular insufficiency (i.e. recent myocardial infarction, acute myocarditis, and uncontrolled symptomatic heart failure)~* Participants with cognitive or physical impairment leading to inability to exercise~* Cancer survivors with severe anaemia (i.e. Haemoglobin \< 8g/dl), symptoms of unusual fatigue, disorientation, faintness, pallor, blurred vision, ataxia, acute nausea and vomiting during the exercise session~* Participants with immunosuppression (i.e. WBC \< 500/mm3), absolute neutrophil count \< 0.5×10 9μl and thrombocytopenia (Platelet count \< 50× 109μl)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): Unsupervised activity
- Functional Resistance Training (FRT) (Type: EXPERIMENTAL): Supervised, group-based functional resistance training

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Patient admitted to any medical or surgical department in the participating centre~* Documented urinary tract infection (other than cystitis), with or without bacteremia, caused by ESBL-producing E. coli susceptible in vitro to cefoxitin (minimal inhibition concentration \<= 8 mg/L and /or diameter ≥ 19 mm according to CA-SFM 2015) and resistant to fluoroquinolones and to association trimethoprim-sulfamethoxazole. An E. Coli urinary tract infection is defined according to SPILF 2014 Clarification by a leucocytury ≥ 104/mL and clinical significant limit at 103 UFC/ml, for the men or the women.~* Medical examination prior to inclusion~* Informed consent signed by the patient~* Patient affiliated to a French Sécurité Social regimen~Exclusion Criteria:~* Serious infection (severe sepsis, septic shock)~* Pregnant or breast-feeding women~* Chronic kidney failure (creatinine clearance \< 30 ml/min) and/or dialysis~* Hypersensibility to imipenem/cilastatine, to cefoxitine~* Hypersensibility to another antibiotics of cephalosporine class~* Hypersensibility to another antibiotics of carbapenem class~* Severe hypersensibility (ex :anaphylactic reaction, or serious cutaneous reaction) to all other antibiotics from beta lactamines family (ex : penicillins, monobactam)~* Treatment with ganciclovir and/or valproic acid~* Infection on the urinary cathether~* Empirical antibiotic therapy including an aminoglycoside~* Patient being treated with antibiotic(s) for another infection~* Patient participating to another interventional study~* Patient not compliant according to the investigator's opinion~* Patient under guardianship

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cefoxitin (Type: EXPERIMENTAL): Cefoxitin 2 g administered intravenously three times a day. during 10 days for the treatment of pyelonephritis during 21 days for the treatment of prostatitis
- imipenem (Type: ACTIVE_COMPARATOR): Imimpenem 1 g administered intravenously three times a day. during 10 days for the treatment of pyelonephritis during 21 days for the treatment of prostatitis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Computer-assisted Delivery of Cognitive Behavioral Therapy for Mental Health and Addictions in Canada

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* In order to create as representative a sample as possible, the inclusion criteria will be fairly broad, including any consenting individual who reports substance abuse in the past thirty days.~* Individuals who are struggling with substance abuse (the definition of 'abuse' is determined by their counselor).~* Individuals who are 18 years of age or older~* Individuals who have used their substance of choice within the past 28 days.~Exclusion Criteria:~* Individuals who are currently suicidal, homicidal, or require immediate hospitalization will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control (Type: NO_INTERVENTION): this arm receives treatment as usual and no intervention.
- CBT4CBT (Type: EXPERIMENTAL): This arm receives treatment as usual and in addition are given access to an online therapy, cbt4cbt. If placed in this group, individuals are asked to use the online therapy for a minimum of 30 minutes each week for the trial duration of 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Able to comply with the study protocol, in the investigator's judgment~* Completion of Study GA30044 up to 48 weeks~* Acceptable safety and tolerability during Study GA30044 as determined by the investigator~Exclusion Criteria:~* Met protocol-defined treatment-stopping criteria during Study GA30044~* An adverse event in Study GA30044 that required permanent discontinuation of study drug~* In the opinion of the investigator, any new, significant, uncontrolled comorbidity or new clinical manifestation (related to SLE or not) that requires medications not allowed in this protocol; or could put the participant at undue risk from a safety perspective~* Any uncontrolled or clinically significant laboratory abnormality that would affect safety, interpretation of study data, or the participant's participation in the study in the opinion of the investigator in consultation with the Medical Monitor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 76 Years
- Healthy Volunteers: f

Study Arms:
- GDC-0853 (200mg) BID (Type: EXPERIMENTAL): Participants previously enrolled in the parent GA30044 Study, now received GDC-0853 (200mg) orally twice daily (BID).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hyperkalemia, defined as K+ ≥5.8 obtained via local laboratory or point-of-care testing~* Written informed consent obtained.~Exclusion Criteria:~1. Clinically significant arrhythmia, defined as any arrhythmia requiring ongoing IV antiarrhythmic therapy.~2. Patients who are hemodynamically unstable, defined as mean arterial pressure ≤65 mmHg or heart rate ≤40 beats per minute or ≥125 beats per minute at time of screening~3. Hyperkalemia solely due to overdose on potassium supplements~4. Known bowel obstruction~5. Subjects currently being treated with or having taken potassium binders (e.g., patiromer, sodium or calcium polystyrene sulfonate or sodium zirconium cyclosilicate) in the 7 days prior to baseline~6. Subjects expected to receive dialysis during the first 6 hours of the study treatment period~7. Known hypersensitivity to patiromer or its ingredients~8. Participation in any other investigational device or drug study \<30 days prior to screening, or current treatment with other investigational agent(s)~9. Inability to consume the investigational product or, in the opinion of the Investigator unsuitable for study participation~10. Life expectancy of less than 6 months~11. Patients with automatically timed medication orders to control potassium in the ED~12. Patient is known to be pregnant or breastfeeding~13. An employee of investigational site or sponsors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Veltassa (Type: ACTIVE_COMPARATOR): 3 packets of study drug powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink while in the emergency department
- Placebo (Type: PLACEBO_COMPARATOR): 3 packets of study drug powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink while in the emergency department

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cell Therapy in Chagas Cardiomyopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of dilated cardiomyopathy according to WHO criteria~* Syndromic heart failure in functional class III or IV of the NYHA~* Enrollment and continuous follow-up in cardiac out-patient clinic~* Adequate medical therapy after optimization therapy~* Echocardiogram with an ejection fraction equal to or less than 35% by Simpson's rule~Exclusion Criteria:~* Valvular diseases, except functional mitral or tricuspid reflow~* Coronariography showing a significant lesion (obstruction of at least 50% of the lumen in the troncus or the main arteries - LAD, CX, RC) in one or more arteries~* Serologic diagnosis for Chagas disease or at least two of the following criteria: epidemiology, right bundle branch block, anterior hemi-block, apical aneurism~* Sustained ventricular tachycardia~* Abusive use of alcohol or illicit drugs~* Pregnancy~* Use of cardio toxic drugs~* Any co-morbidity with impact in life expectancy in 2 years~* Renal function compromised (creatinine above 2 mg/dl)~* Definitive implant of pace-makers, resynchronizers and CDIs~* Heart failure with symptoms initiating less than 1 year ago~* Active systemic arterial hypertension or history of hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Stem Cell therapy (Type: EXPERIMENTAL): Stem Cell therapy
- Standart therapy (Type: ACTIVE_COMPARATOR): Standart therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Questionnaires and Cognitive Assessments Following Mammography

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Mammography Breast Imaging Reporting and Data System (BI-RAD) 4-5; or BI-RAD 1-2~* Fluent in English~* Access to Internet~* Ability to understand and the willingness to sign a written informed consent~Exclusion Criteria:~* Prior abnormal mammography~* Prior cancer diagnosis~* Prior treatment with chemotherapy

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Observational (questionnaires, cognitive assessment) (Type: None): Patients complete questionnaires and cognitive assessments over 45-60 minutes within 3 weeks following mammography and at about 3 months in patients for whom biopsy is not required, before biopsy and at about 3 months in patients for whom biopsy is required, and at 4-6 weeks after first chemotherapy infusion in patients receiving chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Early Stage Amyotrophic Lateral Sclerosis Phrenic Stimulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis is laboratory-supported probable, probable, or definite according to the World Federation of Neurology El Escorial criteria~* Forced Vital Capacity (FVC) from 80 - 60% of predicted values at enrollment~* Bilateral phrenic nerve function acceptable as demonstrated by bilateral diaphragm EMG recordings and nerve conduction times without axonal lesion~Exclusion Criteria:~* Active cardiovascular disease that would increase the risk of general anesthesia. (FEVG\<60%)~* Underlying pulmonary diseases that were present prior to ALS that would effect pulmonary tests independent of ALS, in particular COPD with FEV1\<30%~* Pre-existing implanted electrical device such as a pacemaker or cardiac defibrillator~* respiratory infection or decompensation in the last 30 days~* Marked obesity affecting suitability for surgery~* Significant scoliosis or chest deformity affecting suitability for surgery~* Pre-existing diaphragm abnormality such as a hiatal hernia or paraesophageal hernia~* Patient on NIV, CPAP or Oxygen for a reason other than ALS~* Criteria for NIV (VC\<50% of predicted values and/or Pi max and SNIP\<60% of predicted values; and/or nocturnal desaturations without SAOS and/or PaCO2\>45 mm d'Hg)~* Supine VC\<50% of predicted values

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- phenic nerve stimulation (Type: EXPERIMENTAL): effective phenic nerve stimulation NeurX™ (Synapse Biomedical)
- sham (Type: SHAM_COMPARATOR): sham phenic nerve stimulation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Lactobacillus Acidophilus/Rhamnosus Combination for the Prevention of Antibiotic-associated Diarrhea in the Elderly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Inpatients over the age of 60 on 4A/B unit at Victoria General Hospital, Victoria BC, and~* Anticipated to receive antibiotics (intravenous or oral) for greater than 72 hours for any indication, and~* Are determined to be competent by the prescriber.~Exclusion Criteria:~* Patients who have been on antibiotics during the past 2 weeks~* Patients who have active diarrhea at enrollment~* Patients who have been diagnosed with CDI within the previous 3 months~* Patients who are lactose intolerant~* Patients who have an underlying chronic GI tract disease (inflammatory bowel disease, irritable bowel syndrome)~* Patients who have an ileostomy or colostomy~* Patients who regularly take probiotics~* Patients who are severely immunocompromised (HIV positive, transplant patient, on antirejection medications, on a steroid for \>30 days, or chemotherapy or radiotherapy within the last year)~* Patients who have a life-threatening illness~* Patients who cannot take medications by mouth or are tube fed~* Patients who have been on the new antibiotic for more than 72 hours~* Patients who are anticipated to receive the new antibiotic for a duration of less than 72 hours~* Patients who do no give informed consent.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lactobacillus acidophilus/rhamnosus (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues